The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
The ED50 was determined by its ability to intensify the IL-6 induced growth inhibition of murine M1 cells is ≤ 5.0 ng/ml, in the presence of 20 ng/ml of rhIL-6.
% SDS-PAGE. ab50082 purity is greater than 98% by SDS-PAGE and HPLC analyses.
Endotoxin level is less than 0.1 ng per µg (1EU/µg).
ab50082 expression system is HEK 293 cells.
ab50082 corresponds to the recombinant human soluble IL-6R, which is a 37.6 kDa protein consisting of the extracellular domain of the IL-6R chain (339 amino acid residues).
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. The lyophilized protein is stable for a few weeks at room temperature. Store at -20°C long term.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Reconstitute to 1mg/ml in distilled water.
IL 6R 1
IL 6R alpha
IL-6 receptor alpha chain
IL-6 receptor subunit alpha
IL-6R subunit alpha
Interleukin 6 receptor
interleukin 6 receptor, alpha
Interleukin-6 receptor subunit alpha
Membrane glycoprotein 80
Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal. Signal activation necessitate an association with IL6ST. Activation may lead to the regulation of the immune response, acute-phase reactions and hematopoiesis. Low concentration of a soluble form of IL6 receptor acts as an agonist of IL6 activity.
Isoform 2 is expressed in peripheral blood mononuclear cells and weakly found in urine and serum.
Belongs to the type I cytokine receptor family. Type 3 subfamily. Contains 1 fibronectin type-III domain. Contains 1 Ig-like C2-type (immunoglobulin-like) domain.
The two fibronectin type-III-like domains, contained in the N-terminal part, form together a cytokine-binding domain. The WSXWS motif appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding.
A short soluble form may also be released from the membrane by proteolysis.